Galenica posts solid sales growth for 2013 and confirms double-digit growth in profit
The Galenica Group increased consolidated net sales by 2.0% to CHF 3,359.4 million in 2013, in a market environment char…
The Galenica Group increased consolidated net sales by 2.0% to CHF 3,359.4 million in 2013, in a market environment char…
The Galenica Group performed well in a complex market environment during the first six months of 2013. Net sales increas…
Despite a tense economic situation and global pressure on healthcare costs, the Galenica Group has posted a good result…
The Galenica Group posted new record results for 2011, achieving its 16th consecutive year of double-digit profit growth…
Despite the currency crisis and a difficult economic environment, the Galenica Group contin-ued to grow in 2011 and gene…
Galenica has been strongly affected by the significant drop of both dollar and euro. While the Group generates around tw…
Riemser Arzneimittel AG and Belgian company Ecuphar N.V. have announced that they have agreed on the sale of a large par…
The rich-in-tradition, Saxony-based APOGEPHA pharmaceuticals company is an established producer of urology drugs and the…
Galenica managed to achieve its ambitious targets again in 2008, even though the Group implemented many major projects r…